Scientists

Overview

Partnerships are a key component of our strategy to discover and develop best-in-class treatments for cancer and autoimmune diseases.

Sareum’s partnering strategy has three distinct components to maximise the value of its discovery capabilities and development assets:

  • Collaborative research - We work with partners to advance our drug development programmes and maximise the value in readiness for out-licensing agreements. 
  • Out-licensing – We aim to out-license our development programmes to pharmaceutical and biotechnology partners at the preclinical or early clinical stages. Out-license agreements typically consist of an upfront payment, development milestone payments and sales royalties. 
  • In-licensing – To maintain our product pipeline we continue to investigate sources of new research opportunities. 

For further information on partnering with Sareum on our development-stage projects, or strategic research partnerships, please contact bd (at) sareum.co.uk

  • @Sareumplc Latest tweet

    Roche's discontinuation of its CHK1 inhibitor, RG7741 (aka Genentech's GDC-0575), means this mechanism is now a two… https://t.co/xq9zzVT44p via @Sareumplc
    View more